Wall Street Zen Downgrades Haemonetics (NYSE:HAE) to Hold

Key Points

• Wall Street Zen downgraded Haemonetics from Buy to Hold, adding to a more cautious analyst tone around the stock.
• Other firms also trimmed their outlooks, including Mizuho lowering its target to $70 and JPMorgan cutting its target to $62 while keeping a Neutral rating. Overall, analysts still lean slightly positive with a consensus Moderate Buy and average target of $79.89.
• Despite the mixed ratings, Haemonetics posted a Q4 earnings beat with EPS of $1.29 and revenue of $346.35 million, both above estimates. The company also raised guidance, projecting FY 2027 EPS of $5.258-$5.307 and continued revenue growth.

Haemonetics (NYSE:HAE - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a note issued to investors on Saturday.

Several other equities analysts also recently issued reports on HAE. Mizuho cut their price objective on shares of Haemonetics from $80.00 to $70.00 and set an "outperform" rating on the stock in a report on Monday, April 13th. JPMorgan Chase & Co. cut their price objective on shares of Haemonetics from $74.00 to $62.00 and set a "neutral" rating on the stock in a report on Friday. Barrington Research set a $94.00 price objective on shares of Haemonetics in a report on Friday, February 6th. BTIG Research restated a "buy" rating and set a $88.00 price objective on shares of Haemonetics in a report on Friday, February 6th. Finally, Robert W. Baird set a $67.00 price objective on shares of Haemonetics in a report on Friday. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $79.89.

Haemonetics Stock Performance

HAE opened at $55.06 on Friday. Haemonetics has a 52-week low of $47.31 and a 52-week high of $87.32. The company has a quick ratio of 1.15, a current ratio of 2.95 and a debt-to-equity ratio of 1.53. The company has a market cap of $2.56 billion, a P/E ratio of 27.26, a price-to-earnings-growth ratio of 1.06 and a beta of 0.53. The firm's 50-day moving average price is $59.53 and its 200-day moving average price is $66.68.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.01. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The firm had revenue of $346.35 million for the quarter, compared to the consensus estimate of $336.83 million. During the same quarter in the prior year, the company posted $1.24 earnings per share. The company's revenue for the quarter was up 4.8% compared to the same quarter last year. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. As a group, equities analysts anticipate that Haemonetics will post 5.28 EPS for the current fiscal year.

Hedge Funds Weigh In On Haemonetics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Kemnay Advisory Services Inc. acquired a new position in Haemonetics in the 4th quarter worth approximately $26,000. True Wealth Design LLC increased its holdings in Haemonetics by 6,700.0% in the 4th quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier's stock worth $27,000 after buying an additional 335 shares during the period. Leonteq Securities AG acquired a new position in Haemonetics in the 4th quarter worth approximately $30,000. EverSource Wealth Advisors LLC increased its holdings in Haemonetics by 2,640.0% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier's stock worth $31,000 after buying an additional 396 shares during the period. Finally, Kestra Advisory Services LLC acquired a new position in Haemonetics in the 4th quarter worth approximately $34,000. Institutional investors and hedge funds own 99.67% of the company's stock.

Key Stories Impacting Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Haemonetics reported fiscal Q4 results that topped expectations, with EPS of $1.29 vs. $1.28 expected and revenue of $346.35 million vs. $336.83 million expected, while revenue rose 4.8% year over year. Haemonetics NYSE: HAE Reports Upbeat Q1 CY2026
• Positive Sentiment: The company also guided FY 2027 EPS to $5.258-$5.307 and reiterated revenue around $1.4 billion, signaling continued growth from Persona PLUS rollout and a rebound in IVT volumes. Haemonetics projects FY 2027 revenue growth of 4% to 7% as Persona PLUS rollout and IVT rebound efforts continue
• Neutral Sentiment: JPMorgan lowered its price target on Haemonetics to $62 from $74 and kept a Neutral rating, reflecting more cautious expectations even though the new target still sits above the recent share price. Read More
• Neutral Sentiment: Several earnings call transcripts and summaries were published, but they mainly reinforce the same themes of modest earnings beats and management’s forward guidance. Haemonetics (HAE) Q4 2026 Earnings Transcript

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company's offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company's product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.